INCREASED ANDROGEN RECEPTOR ACTIVITY AND ALTERED C-MYC EXPRESSION IN PROSTATE-CANCER CELLS AFTER LONG-TERM ANDROGEN DEPRIVATION

被引:0
|
作者
KOKONTIS, J
TAKAKURA, K
HAY, N
LIAO, SS
机构
[1] UNIV CHICAGO, BEN MAY INST, CHICAGO, IL 60637 USA
[2] UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA
[3] UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proliferation of LNCaP 104-S cells, a clonal subline of the human prostate cancer cell line, was very slow in androgen-depleted medium but increased 10-13-fold in the presence of 0.1 nM of a synthetic androgen, R1881. This induction of proliferation was diminished at higher concentrations of R1881, indicating the biphasic nature of the androgen effect. After 20-30 passages in androgen depleted medium, these cells progressed to 104-I cells, which exhibited much lower proliferative sensitivity to 0.1 nM R1881. After another 20-30 passages, LNCaP 104-I cells gave rise to 104-R cells, which proliferated rapidly without additional androgen. Proliferation of 104-R cells was induced 2-fold by 0.01 nM R1881 but was repressed by 0.1 nM R1881 and above. Thus, androgen induction and repression of proliferation could be seen at lower concentrations of androgen as the cells progressed. During the transition of 104-S cells to 104-R cells, the androgen receptor mRNA level increased 2.5-fold whereas the androgen receptor protein level increased 15-fold in the absence of androgen. Androgen receptor transcriptional activity, measured by androgen induction of prostate-specific antigen mRNA. and chloramphenicol acetyltransferase activity in transfected cells, increased up to 20-fold during the progression. LNCaP cells, therefore, appear to be able to adapt to reduced androgen availability by increasing their sensitivity to androgen, raising questions concerning the therapeutic strategies used against prostate cancer. Androgen induction of c-myc expression in 104-R cells occurred at a 10-fold lower concentration (0.01 nM) than in 104-S cells (0.1 nM). In all stages, cell proliferation and c-myc expression were repressed by androgen at a high concentration (20 nM), but the repression of cell proliferation was blocked by retroviral overexpression of c-myc.
引用
收藏
页码:1566 / 1573
页数:8
相关论文
共 50 条
  • [21] Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
    Sena, Laura A.
    Kumar, Rajendra
    Sanin, David E.
    Thompson, Elizabeth A.
    Rosen, D. Marc
    Dalrymple, Susan L.
    Antony, Lizamma
    Yang, Yuhan
    Gomes-Alexandre, Carolina
    Hicks, Jessica L.
    Jones, Tracy
    Bowers, Kiara A.
    Eskra, Jillian N.
    Meyers, Jennifer
    Gupta, Anuj
    Skaist, Alyza
    Yegnasubramanian, Srinivasan
    Luo, Jun
    Brennen, W. Nathaniel
    Kachhap, Sushant K.
    Antonarakis, Emmanuel S.
    De Marzo, Angelo M.
    Isaacs, John T.
    Markowski, Mark C.
    Denmeade, Samuel R.
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (23):
  • [22] ABNORMAL ANDROGEN RECEPTOR EXPRESSION AND GENE STRUCTURE IN HUMAN PROSTATE-CANCER
    BARRACK, ER
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 222 - 222
  • [23] Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy
    Chan, Jeffrey Shi Kai
    Lee, Yan Hiu Athena
    Liu, Kang
    Hui, Jeremy Man Ho
    Dee, Edward Christopher
    Ng, Kenrick
    Satti, Danish Iltaf
    Tang, Pias
    Tse, Gary
    Ng, Chi Fai
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53 (04)
  • [24] Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy
    Braga-Basaria, M
    Muller, D
    Carducci, M
    Egan, J
    John, M
    Dobs, A
    Basaria, S
    JOURNAL OF ANDROLOGY, 2006, : 92 - 92
  • [25] Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer
    Morote, Juan
    Morin, Jacques Planas
    Orsola, Anna
    Abascal, Jose M.
    Salvador, Caries
    Trilla, Enrique
    Raventos, Caries X.
    Cecchini, Lluis
    Encabo, Gloria
    Reventos, Jaume
    UROLOGY, 2007, 69 (03) : 500 - 504
  • [26] Cognitive effects of long-term androgen deprivation therapy in older men with prostate cancer
    Pergolizzi, Denise
    Flaherty, Kathleen R.
    Saracino, Rebecca M.
    Root, James C.
    Schofield, Elizabeth
    Cassidy, Caroline
    Katheria, Vani
    Patel, Sunita K.
    Dale, William
    Nelson, Christian J.
    PSYCHO-ONCOLOGY, 2024, 33 (03)
  • [27] Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy
    Schulman, C.
    Irani, J.
    Aapro, M.
    BJU INTERNATIONAL, 2012, 109 : 13 - 21
  • [28] Long-term health care costs for prostate cancer patients on androgen deprivation therapy
    Krahn, M. D.
    Bremner, K. E.
    Luo, J.
    Tomlinson, G.
    Alibhai, S. M. H.
    CURRENT ONCOLOGY, 2016, 23 (05) : E443 - E453
  • [29] A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy
    Gregory, CW
    He, B
    Johnson, RT
    Ford, OH
    Mohler, JL
    French, FS
    Wilson, EM
    CANCER RESEARCH, 2001, 61 (11) : 4315 - 4319
  • [30] Epigenetic setting for long-term expression of estrogen receptor a and androgen receptor in cells
    Imamura, Takuya
    HORMONES AND BEHAVIOR, 2011, 59 (03) : 345 - 352